{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:28Z","timestamp":1786120348211,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/wnf.0b013e3182281c25","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T19:00:11Z","timestamp":1317754811000},"page":"201-202","source":"Crossref","is-referenced-by-count":1,"title":["Milnacipran in Panic Disorder With Agoraphobia and Major Depressive Disorder"],"prefix":"10.1097","volume":"34","author":[{"given":"Mu-Hong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jay","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2","key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00004850-199506000-00003","article-title":"Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale.","volume":"10","author":"Bandelow","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.npp.1300880","article-title":"Serotonin function in panic disorder: important, but why?","volume":"31","author":"Maron","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0006-3223(99)00246-2","article-title":"The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias.","volume":"46","author":"Sullivan","year":"1999","journal-title":"Biol Psychiatry"},{"issue":"7","key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archpsyc.1997.01830190069007","article-title":"Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder.","volume":"54","author":"Coplan","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archpsyc.55.9.801","article-title":"Lifetime panic-depression comorbidity in the National Comorbidity Survey.","volume":"55","author":"Kessler","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J","article-title":"Comorbid depression and anxiety spectrum disorders.","volume":"4","author":"Gorman","year":"1996","journal-title":"Depress Anxiety"},{"issue":"6","key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/WNF.0b013e3181ac155b","article-title":"Milnacipran: beyond a role of antidepressant.","volume":"32","author":"Pae","year":"2009","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/YIC.0b013e32802c7bf5","article-title":"The efficacy of milnacipran in panic disorder: an open trial.","volume":"22","author":"Blaya","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pbb.2005.04.015","article-title":"Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action.","volume":"81","author":"Bourin","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbr.2005.05.017","article-title":"Alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.","volume":"164","author":"Masse","year":"2005","journal-title":"Behav Brain Res"},{"issue":"3","key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1871524911006030207","article-title":"The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and panic disorders.","volume":"10","author":"Graeff","year":"2010","journal-title":"Cent Nerv Syst Agents Med Chem"},{"issue":"3","key":"R12-8-20210203","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11064-008-9818-2","article-title":"Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats.","volume":"34","author":"Muneoka","year":"2009","journal-title":"Neurochem Res"},{"issue":"5","key":"R13-8-20210203","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.pneurobio.2004.09.004","article-title":"Mesolimbic dopaminergic pathways in fear conditioning.","volume":"74","author":"Pezze","year":"2004","journal-title":"Prog Neurobiol"},{"issue":"1","key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1176\/appi.ajp.2009.09030410","article-title":"Overgeneralization of conditioned fear as a pathogenic marker of panic disorder.","volume":"167","author":"Lissek","year":"2010","journal-title":"Am J Psychiatry"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201109000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:49Z","timestamp":1786047889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201109000-00008"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3182281c25","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}